TOBRADEX ST
LOE Approachingtobramycin / dexamethasone
NDAOPHTHALMICSUSPENSION/DROPS
Approved
Feb 2009
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
5/8 — Partial
TOBRADEX ST (tobramycin / dexamethasone) is corticosteroid hormone receptor agonists [moa]. Approved for inflammatory conditions of the palpebral, bulbar conjunctiva, cornea and 7 more indications. First approved in 2009.
Drug data last refreshed 4d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TOBRADEX ST is a fixed-dose ophthalmic suspension combining tobramycin (antibiotic) and dexamethasone (corticosteroid) for treating inflammatory conditions of the anterior segment of the eye. It works by inhibiting the inflammatory cascade through phospholipase A2 inhibition while providing broad-spectrum antimicrobial coverage. The formulation is indicated for post-operative inflammation, uveitis, corneal injury from chemical/thermal burns, and steroid-responsive inflammatory conditions where infection risk is acceptable.
$4.0MPart D
LOE Approaching2.2 years to LOEProduct is entering loss-of-exclusivity phase with modest Part D spending ($4M) and moderate claim volume (13,756), signaling a mature brand in transition toward generic competition with likely workforce consolidation.
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Pharmacologic Class:
Corticosteroid
Indications (10)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.